KMT2A and leukemia: More recently, Godfrey et al. [106] reported that, in MLL-AF4 leukaemia cells, this epigenetic marker H3K79me2/3 controls E–P interactions and further activates pan-cancer stem cell marker protein PROM1/CD133.